Author

C. Luck

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Approach:experimental assay· 4 Assay:bulk RNA-seq· 3 Research Focus:cell type annotation· 3 Research Focus:drug response / drug discovery· 3 Approach:statistical model· 3 Research Focus:differential expression· 2 Assay:whole-genome sequencing· 2

Frequent Co-Authors

K. Yu· 2 shared M. Sirota· 2 shared R. A. Okimoto· 2 shared A. B. Vaidya· 1 shared A. G. Lee· 1 shared A. L. Koehne· 1 shared A. Spillinger· 1 shared A. T. Shah· 1 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

K. Yu

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

The Capicua C1 Domain is Required for Full Activity of the CIC::DUX4 Fusion Oncoprotein

C. Luck, K. A. Jacobs, R. A. Okimoto

This study shows that the C1 domain of CIC is required for full activity of the CIC::DUX4 fusion oncoprotein, highlighting the importance of breakpoint location in fusion function.

bioRxiv · Jun 6, 2024 · PreprintCancer Biology

Mapping chromatin state and transcriptional response in CIC-DUX4 undifferentiated round cell sarcoma

N. Thomas, C. Luck, N. Shlimon, R. Kriska Ponce, Z. Kosibaty, R. Okimoto

This study identifies CIC-DUX4-mediated chromatin states and transcriptional responses in sarcoma using ChIP and RNA-Seq analysis of patient-derived cells.

bioRxiv · Oct 11, 2023 · PreprintCancer Biology

Development and characterization of new patient-derived xenograft (PDX) models of osteosarcoma with distinct metastatic capacities

C. R. Schott, A. L. Koehne, L. C. Sayles, E. P. Young, C. Luck, K. Yu, A. G. Lee, M. R. Breese, S. G. Leung, A. T. Shah, H. Xu, H.-Y. Liu, A. Spillinger, I. H. Behroozfard, K. D. Marini, , E. A. Sweet-Cordero

The paper develops and characterizes new osteosarcoma PDX models with varying metastatic capacities to study disease biology and test therapeutic interventions.

bioRxiv · Jan 19, 2023Cancer Biology

Allosteric SHP2 Inhibition Increases Apoptotic Dependency on BCL2 and Synergizes with Venetoclax in FLT3- and KIT- Mutant AML

B. Popescu, C. Stahlhut, T. C. Tarver, S. Wishner, B. J. Lee, C. A. C. Peretz, C. Luck, P. Phojanakong, J. A. Camara Serrano, H. Hongo, J. M. Rivera, S. Xirenayi, J. A. Chukinas, V. Steri, S. K. Tasian, , C. C. Smith

This study shows that combining SHP2 and BCL2 inhibition synergistically kills FLT3- and KIT-mutant AML cells and xenografts.

bioRxiv · Dec 1, 2022 · PreprintCancer Biology

Transcriptional fidelity enhances cancer cell line selection in pediatric cancers

C. Luck, K. Yu, R. A. Okimoto, M. Sirota

This study evaluates how well cancer cell lines represent pediatric tumors using RNA-seq data, finding that most tumor types best correlate with cell lines of the closest disease type.

bioRxiv · Oct 1, 2021 · PreprintCancer Biology

Atypical molecular basis for drug resistance to mitochondrial function inhibitors in Plasmodium falciparum

H. J. Painter, J. M. Morrisey, M. W. Mather, L. M. Orchard, C. Luck, M. J. Smilkstein, M. K. Riscoe, A. B. Vaidya, M. Llinas

This study identifies a novel mechanism of drug resistance in Plasmodium falciparum involving copy number variation and a SNP in pfdhodh, leading to pan-resistance to mtETC and DHODH inhibitors.

bioRxiv · Oct 8, 2020Microbiology